. 2019 May 30;18:1536012119846025. doi: 10.1177/1536012119846025

Table 3.

Univariate Analysis for Clinical Factors and PET/CT Parameters Related to PFS and OS.

Clinical Factors and Parameters		Median PFS, Months	P	Median OS, Months	P
Gender	Male	8.4	.004	26.6	.04
Gender	Female	6.2	.004	21.5	.04
Age	≤58	7.4	.032	31.7	.018
Age	>58	5.8	.032	20.7	.018
Smoking status	No	8.2	.025	24.6	.382
Smoking status	Yes	5.4	.025	19.9	.382
PET/CT stage	I	9.6	.0	55.5	.0
	II	8.4		37.8
	III	7.6		29.9
	Ⅳ	5.7		17.4
Histology	Adenocarcinoma	6.7	.002	25.5	.051
	Squamous cell carcinoma	8.1		21.1
	Poorly differentiated NSCLC	4.8		21.5
	Others	5.2		32.9
Differentiation degree	Well-differentiated	23.4	.0	49.1	.014
	Moderately differentiated	13.6		48.3
	Poorly differentiated	5.2		21.1
Type of surgery	Lobectomy	12.7	.0	48.6	.0
	Pneumonectomy	10.5		35.6
	Others	8		19.3
	No surgery	6		19.3
Chemotherapy regimen	PMX-based	7	.013	29.4	.001
	PTX-based	5.2		20.7
	GEMZ-based	6.3		23.1
	TXT-based	7.7		19.4
Adjuvant radiotherapy	No	6.3	.932	21.5	.725
Adjuvant radiotherapy	Yes	7	.932	26.6	.725
Targeted therapy	No	6.4	.782	23	.812
Targeted therapy	Yes	7.2	.782	21.8	.812
SCC, ng/mL	≤1.5	7	.005	27.4	.001
SCC, ng/mL	>1.5	5.2	.005	13.3	.001
CEA, ng/mL	≤5.0	7.6	.038	31	.155
CEA, ng/mL	>5.0	6.5	.038	21.6	.155
NSE, ng/mL	≤15.2	6.5	.071	29.1	.1
NSE, ng/mL	>15.2	6.6	.071	20.7	.1
SUVmax	≤11.72	7	.798	24.7	.886
SUVmax	>11.72	6.5	.798	21.7	.886
MTV50	≤4.04	8.2	.034	34.5	.021
MTV50	>4.04	6	.034	18.1	.021
TLG50	≤34.55	7.6	.094	29.3	.052
TLG50	>34.55	6.3	.094	19.3	.052

Abbreviations: CEA, carcinoembryonic antigen; CT, computed tomography; GEMZ, gemcitabine; MTV, metabolic tumor volume; NSCLC, non-small cell lung cancer; NSE, neuron-specific enolase; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival; PMX, pemetrexed; PTX, paclitaxel; SCC, squamous cell carcinoma antigen; SUVs, standardized uptake values; TLG, total lesion glycolysis; TXT, docetaxel.